Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.
- Published In:
- Diabetes, obesity & metabolism, 28(1), 166-173 (2026)
- Authors:
- Al Ozairi, Ebaa, Irshad, Mohammad, Alkandari, Jumana, Sojan, Litty, Alroudhan, Dherar, Alotaibi, Nourah, le Roux, Carel W
- Database ID:
- RPEP-14724
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14724APA
Al Ozairi, Ebaa; Irshad, Mohammad; Alkandari, Jumana; Sojan, Litty; Alroudhan, Dherar; Alotaibi, Nourah; le Roux, Carel W. (2026). Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.. Diabetes, obesity & metabolism, 28(1), 166-173. https://doi.org/10.1111/dom.70172
MLA
Al Ozairi, Ebaa, et al. "Weight loss in people with type 1 diabetes over 12 months: Real-world data comparing tirzepatide, semaglutide and liraglutide.." Diabetes, 2026. https://doi.org/10.1111/dom.70172
RethinkPeptides
RethinkPeptides Research Database. "Weight loss in people with type 1 diabetes over 12 months: R..." RPEP-14724. Retrieved from https://rethinkpeptides.com/research/al-2026-weight-loss-in-people
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.